NCT05448443已完成2 期
Crossover, Double-blind, Phase 2 Study of AD981 Versus Placebo in Obesity Hypoventilation Syndrome
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 15
- 试验地点
- 1
- 主要终点
- Nocturnal transcutaneous CO2 pressure (PtcCO2)
研究概览
简要总结
This is a randomized, double blind, placebo-controlled, cross-over, phase II, single center efficacy study of AD981 in patients with obesity hypoventilation syndrome documented by polysomnography (PSG) and transcutaneous, overnight measurement of CO2 (PtcCO2).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Be able to understand the nature of the study and sign the informed consent
- •BMI > 35 kg/m2 and presence of nocturnal hypoventilation
- •Previous surgical treatment for OSA is allowed if ≥ 1 year prior to enrollment
- •If in treatment, CPAP or BPAP or mandibular advancement device or positional therapy intolerance or poor compliance
排除标准
- •Narcolepsy, craniofacial malformation, renal failure, hepatic disease, schizophrenia, schizoaffective disorder or bipolar disorder, cognitive dysfunction, severe neurological disorder, pheochromocytoma, adrenocortical insufficiency, hyperchloremic acidosis.
- •Respiratory (COPD, ILD, oxygen therapy) or cardiac (Heart Failure, Atrial fibrillation, established severe peripheral arterial disease) disease or hypertension requiring more than 3 medications for control
- •Cardiomyopathies, heart malformation or structural heart alterations, severe rhythm disorders, established coronary heart disease or other cardiac conditions, which could determine sudden death
- •Attempted suicide or suicidal ideation
- •Drugs of abuse or substance use disorder
- •A significant illness or infection requiring medical treatment in the past 30 days.
- •Untreated narrow angle glaucoma.
- •Women who are pregnant or nursing.
- •Treatment with strong cytochrome P450 3A4 (CYP3A4) inhibitors, or monoamine oxidase inhibitors (MAOI) or linezolid within 14 days of the start of treatment, allergies to sulfonamides.
- •Diabetes with unstable glucose control in the past 15 days.
- •> 500 mg/day of Aspirin
- •Low sodium or potassium.
- •Any condition that in the investigator's opinion would present an unreasonable risk to the participant.
- •History of using oral or nasal devices (such as mandibular advancement devices) for the treatment of OSA may enroll as long as the devices are not used during participation in the study for at least 2 weeks prior to study begin.
- •History of using devices to affect participant sleeping position for the treatment of OSA, e.g. to discourage supine sleeping position, may enroll as long as the devices are not used during participation in the study.
- •Use of another investigational agent within 30 days or 5 half-lives, whichever is longer, prior to dosing.
- •Patient currently receiving: MAOIs, Serotonin and Norepinephrine Reuptake Inhibitors, Norepinephrine Reuptake Inhibitors, Lithium, Tricyclic antidepressants, strong CYP2D6 inhibitors, other strong inhibitors cytochrome P450, thiazides diuretics, benzodiazepines, opioids, drugs with clinically significant cardiac QT-interval prolonging effects, drugs known to lower seizure threshold, amphetamines, antiepileptics, modafinil or armodafinil, beta2 agonists, antipsychotics, pseudoephedrine, phenylephrine, oxymetazoline, drugs for Parkinson's, Alzheimer's, Huntington's, Amyotrophic Lateral Sclerosis, or drugs for other neurodegenerative diseases, more than 500 mg/day of Aspirin or salicylates, sodium Phosphate.
- •Known hypersensitivity to study drugs
研究组 & 干预措施
AD981
Experimental
AD981
干预措施: AD981 (Drug)
Placebo
Placebo Comparator
Placebo
干预措施: Placebo (Other)
结局指标
主要结局
Nocturnal transcutaneous CO2 pressure (PtcCO2)
时间窗: From baseline to the last day of treatment (14 days after the start of each treatment period)
次要结局
- Proportion of participants without nocturnal hypoventilation(From baseline to the last day of treatment (14 days after the start of each treatment period))
- Apnea-Hypopnea Index (AHI)(From baseline to the last day of treatment (14 days after the start of each treatment period))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Efficacy, Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Oral Administration of AIM-102 in Patients With Mild to Moderate Allergic AsthmaAsthmaNCT01501942AIM Therapeutics Inc.11
已完成
2 期
Cold Challenge With C21 in RPRaynaud PhenomenonSystemic SclerosisNCT04388176Vicore Pharma AB20
已完成
2 期
Phase 2 Trials of NA-931 to Study Subjects Who Are Obese With at Least One Weight-related Comorbid ConditionWeight LossBody WeightBody Weight ChangesObesityNCT06564753Biomed Industries, Inc.126
已完成
2 期
Study to Evaluate the Efficacy and Safety of SST-6007, a Topical Sildenafil Cream, Compared to Placebo in Women With Female Sexual Arousal DisorderSexual Arousal DisorderNCT02570282Strategic Science & Technologies, LLC31
已完成
2 期
A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic GastroenteritisEosinophilic GastritisEosinophilic GastroenteritisNCT03496571Allakos Inc.65